Arix Bioscience News | finanzen.ch

Arix Bioscience Aktie VALOR 35597915 / ISIN GB00BD045071

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

12.02.24	Scheme Effective (EQS Group)
12.02.24	Suspension of Trading in Shares (EQS Group)
07.02.24	Transaction Update (EQS Group)
29.01.24	Results of First General Meeting (EQS Group)
24.01.24	Holding(s) in Company (EQS Group)
24.01.24	Holding(s) in Company (EQS Group)
23.01.24	Update on the Scheme and Publication of Notice of Second General Meeting (EQS Group)
22.01.24	Update on the Scheme and Resignation of Directors (EQS Group)
19.01.24	Financial update on Harpoon Therapeutics acquisition by Merck (MSD) (EQS Group)
19.01.24	Unaudited NAV for December 2023 (EQS Group)
08.01.24	Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD) (EQS Group)
05.01.24	Publication of Circular and RTW Bio Prospectus (EQS Group)
04.01.24	Holding(s) in Company (EQS Group)
22.12.23	Update regarding timing of Proposed Scheme of Reconstruction (EQS Group)
13.12.23	Unaudited NAV for November 2023 (EQS Group)
08.12.23	Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial (EQS Group)
13.11.23	Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock (EQS Group)
10.11.23	Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock (EQS Group)
10.11.23	PDMR Notification & Director Shareholding (EQS Group)
08.11.23	Unaudited NAV for October 2023 (EQS Group)
03.11.23	PDMR Notification & Director Shareholding (EQS Group)
02.11.23	PDMR Notification & Director Shareholding (EQS Group)
01.11.23	Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102 (EQS Group)
24.10.23	Portfolio company Harpoon Therapeutics announces up to $150 million private placement (EQS Group)
06.10.23	Unaudited NAV for September 2023 (EQS Group)
27.09.23	Board Change (EQS Group)
14.09.23	Notice of Results and Investor Presentation (EQS Group)
14.09.23	Unaudited NAV for August 2023 (EQS Group)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	144.55	2.19 %	K V
Geberit	598.20	1.67 %	K V
Alcon	64.08	0.98 %	K V
Sonova Hldg	239.50	0.80 %	K V
Nestle	75.41	-0.63 %	K V
Zurich Insur Gr	575.40	-0.66 %	K V
UBS Group	32.10	-1.05 %	K V
Swiss Re	140.95	-1.19 %	K V
Swiss Life Hldg	834.00	-1.70 %	K V